Table 1.
Antibiotic susceptibility testing of bacterial isolates from patients of cases 1, 2 and 3, using European Committee on Antimicrobial Susceptibility Testing clinical breakpoints
| Antibiotic | Case 1 | Case 2 | Case 3* |
| Pseudomonas aeruginosa | Streptococcus constellatus | Escherichia coli | |
| Ampicillin | R | ||
| Amoxicillin/clavulanic acid | R | ||
| Penicillin | S | ||
| Cefuroxime | R | ||
| Cefotaxime | R | ||
| Ceftazidime | I | ||
| Cefepime | R | ||
| Erythromycin | S | ||
| Levofloxacin | S | ||
| Ciprofloxacin | R | ||
| Clindamycin | S | ||
| Vancomycin | S | ||
| Ciprofloxacin | S | ||
| Gentamicin | S | S | |
| Meropenem | I | S | |
| Ceftazidime | S | ||
| Piperacillin/tazobactam | R | R | |
| Trimetropim/sulfamethoxazole | R | ||
| Amikacin | R | ||
| ESBL producing bacteria | Positive |
*In case 3, Streptococcus anginosus, Parvimonas micra, Prevotella melaninogenica and Actinomyces odontolyticus were not tested for antibiotic susceptibility.
ESBL, extended-spectrum beta-lactamase; I, intermediate; R, resistant; S, susceptible.